Examining the Moving Average Convergence Divergence (MACD), the weekly chart signals a bearish stance while the monthly chart remains mildly bearish. The Relative Strength Index (RSI) does not currently indicate a definitive signal on either weekly or monthly scales, suggesting a neutral momentum in terms of overbought or oversold conditions. Bollinger Bands present a divergence with weekly readings bearish and monthly readings mildly bullish, highlighting short-term volatility against a longer-term stabilisation attempt.
Fast mover alert! This Large Cap from Automobiles - Passeenger just qualified for our Momentum list with stellar technical indicators. Strike while the iron is hot!
- Recent Momentum qualifier
- Stellar technical indicators
- Large Cap fast mover
Daily moving averages for Panacea Biotec indicate a bearish trend, reinforcing the short-term downward momentum. The Know Sure Thing (KST) indicator shows a mildly bullish signal on the weekly chart but mildly bearish on the monthly, reflecting mixed momentum signals. Dow Theory analysis aligns with a mildly bearish outlook on both weekly and monthly timeframes. On-Balance Volume (OBV) suggests a mildly bearish trend weekly, with no clear trend monthly, indicating volume patterns that do not strongly support price movements.
From a price perspective, Panacea Biotec’s 52-week high is ₹581.00, while the 52-week low is ₹282.15. The stock’s recent trading range today fluctuated between ₹373.00 and ₹395.80, closing below the previous close of ₹389.80. This price action, combined with the technical indicators, points to a cautious environment for investors.
Comparing Panacea Biotec’s returns with the Sensex benchmark reveals a divergence in performance. Over the past week, the stock recorded a return of -5.52% against the Sensex’s 0.96%. The one-month return shows a decline of -15.90% for the stock, while the Sensex gained 0.86%. Year-to-date, Panacea Biotec’s return is -9.69%, contrasting with the Sensex’s 8.36%. Over longer horizons, the stock’s three-year return of 173.36% outpaces the Sensex’s 37.31%, while the five-year return of 95.10% trails the Sensex’s 91.65%. The ten-year return for Panacea Biotec stands at 178.03%, compared to the Sensex’s 232.28%, illustrating varied performance across timeframes.
Considering Panacea Biotec ? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this small-cap with top-rated alternatives now!
- Better options discovered
- Pharmaceuticals & Biotechnology + beyond scope
- Top-rated alternatives ready
Panacea Biotec’s market capitalisation grade remains at 3, reflecting its standing within the Pharmaceuticals & Biotechnology sector. The recent adjustment in its evaluation score, effective from 19 Nov 2025, follows a technical parameter change that has influenced the stock’s momentum profile. Investors should note the mixed signals from various technical indicators, which suggest a nuanced market sentiment rather than a clear directional trend.
In summary, Panacea Biotec’s technical landscape is characterised by a shift towards bearish momentum in the short term, tempered by some mildly bullish signals on longer-term indicators. The divergence between weekly and monthly technical readings underscores the importance of a cautious approach, with attention to evolving price and volume patterns. Market participants analysing Panacea Biotec should consider these technical nuances alongside broader sector and market trends to inform their investment decisions.
Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
